Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma · Plasma Cell Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Contact: Study coordinator (Rachel Kingsford) · rachel.kingsford@hci.utah.edu · 801-585-0115

Study leads

Ghulam Rehman Mohy-ud-din, MBBS
Principal Investigator
Huntsman Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Brain Cancer · Breast Cancer · Bladder Cancer

Abroad (travel likely)Recruiting

Duarte, United States · Miami, United States

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia

Abroad (travel likely)RecruitingPHASE1

Wuhan, China

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Zhengzhou, China · Suzhou, China

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Duarte, United States